Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | KIF11 | P52732 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11652133 | 1.00 | CYP19A1 (0.61) | CYP19A1TSHRKIF11MAPK1HIF1A | |
| SCHEMBL1224870 | 1.00 | CYP19A1 (0.61) | CYP19A1TSHRKIF11MAPK1HIF1A | |
| SCHEMBL7782036 | 0.89 | CYP19A1 (0.65) | CYP19A1TSHRMAPK1HIF1AMEN1 | |
| Chlorotriphenylmethane SCHEMBL461 | 0.86 | TSHR (0.65) | CYP19A1TSHRMAPK1CYP1A2 | |
| Chlorotriphenylmethane SCHEMBL16781670 | 0.86 | TSHR (0.65) | CYP19A1TSHRMAPK1CYP1A2 | |
| SCHEMBL3903209 | 0.84 | TSHR (0.50) | CYP19A1TSHRKIF11MAPK1HIF1A | |
| SCHEMBL7646185 | 0.84 | TSHR (0.50) | CYP19A1TSHRKIF11MAPK1HIF1A | |
| SCHEMBL9577502 | 0.84 | TSHR (0.74) | CYP19A1TSHRKIF11MAPK1HIF1A | |
| Chlorotriphenylmethane SCHEMBL7567317 | 0.83 | TSHR (0.61) | CYP19A1TSHRMAPK1CYP1A2 | |
| Chlorotriphenylmethane SCHEMBL7246540 | 0.83 | TSHR (0.61) | CYP19A1TSHRMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 938 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116808231-B | Cell membrane penetrating peptide coupled sulpride prodrug system, preparation method and application | 中国药科大学 | 2024-03-26 | — | — | CN | claimed |
| CN-114702380-B | Method for co-producing p-chlorobenzoyl chloride and hexanoyl chloride and acyl chloride product thereof | 河南特格纳特科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117659122-A | Carbon monoxide release molecule-transmembrane peptide complex and preparation and application thereof | 中国人民解放军总医院 | 2024-03-08 | — | — | CN | claimed |
| CN-116808231-A | Cell membrane penetrating peptide coupled sulpride prodrug system, preparation method and application | 中国药科大学 | 2023-09-29 | — | — | CN | claimed |
| WO-2023082803-A1 | ACTIVE POLYPEPTIDE FOR INHIBITING GROWTH OF LIVER CANCER CELLS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 华南理工大学 | 2023-05-19 | — | — | WO | claimed |
| CN-110041407-B | Method for synthesizing dessertraline acetate based on Fmoc dipeptide | 南京肽业生物科技有限公司 | 2022-10-28 | — | — | CN | claimed |
| EP-3405476-B1 | METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER | POLYPEPTIDE LABORATORIES HOLDING PPL AB (SE) | 2022-05-18 | — | — | EP | claimed |
| CN-114471005-A | Cell-penetrating peptide transdermal absorption enhancer and preparation device thereof | 赵彬 | 2022-05-13 | — | — | CN | claimed |
| US-11236123-B2 | Method for preparation of peptides with psWang linker | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2022-02-01 | — | — | US | claimed |
| CN-113845571-A | Active polypeptide for inhibiting growth of liver cancer cells and preparation method and application thereof | 华南理工大学 | 2021-12-28 | — | — | CN | claimed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| EP-1373305-A1 | PROCESS FOR PRODUCING TRUNKAMIDE A COMPOUNDS | PHARMA MAR, S.A. (ES) | 2004-01-02 | — | — | EP | claimed |
| WO-2003028720-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-04-10 | — | — | WO | claimed |
| WO-2002081506-A1 | PROCESS FOR PRODUCING TRUNKAMIDE A COMPOUNDS | PHARMA MAR, S.A. (ES) | 2002-10-17 | — | — | WO | claimed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | claimed |
| EP-0937097-B1 | COMPOSITIONS AND METHODS FOR IMMOBILIZING NUCLEIC ACIDS TO SOLID SUPPORTS | SEQUENOM INC (US) | 2001-08-16 | — | — | EP | claimed |
| JP-2001501967-A | — | — | 2001-02-13 | — | — | JP | claimed |
| US-6133436-A | INCREASED SURFACE AREA FOR IMMOBILIZATION OF NUCLEIC ACIDS; FOR USE IN HYBRIDIZATIONS | SEQUENOM, INC. (US) | 2000-10-17 | — | — | US | claimed |
| EP-0937097-A1 | COMPOSITIONS AND METHODS FOR IMMOBILIZING NUCLEIC ACIDS TO SOLID SUPPORTS | SEQUENOM, INC. (US) | 1999-08-25 | — | — | EP | claimed |
| WO-1998020019-A1 | COMPOSITIONS AND METHODS FOR IMMOBILIZING NUCLEIC ACIDS TO SOLID SUPPORTS | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236123-B2 | Method for preparation of peptides with psWang linker | VIP, GLP1R, IAPP | CYP19A1 4442/4885TSHR 852/4885KIF11 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.